Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders
NCT02540538Phase 1Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- Sep 2015
- Primary completion
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HBAI20 in hepatitis B (HBV), sponsored by Maastricht University Medical Center+. Primary endpoint: Subjects With Local and/or General Adverse Events Irrespective of Severity at 7 months. Started Sep 2015; status: completed.
02
Drugs
HBAI20
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT02540538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02540538.